American Story

Should I shadow American Renal Associates (NYSE:ARA) investors?
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of American Renal Associates. In general, we focus on analyzing American Renal stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build American Renal's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of American Renal's intrinsic value. In addition to deriving basic predictive indicators for American Renal, we also check how macroeconomic factors affect American Renal price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research. Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of American Renal's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of American Renal in the context of predictive analytics.

Earnings Estimates (1) Details

Hype Prediction Details

Intrinsic Valuation Details

Naive Forecast Details

2 Analysts Consensus Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as American Renal. Your research has to be compared to or analyzed against American Renal's peers to derive any actionable benefits. When done correctly, American Renal's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in American Renal Assoc.

How does American Stands against Peers?

Analyzing American Renal competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to American Renal across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out American Renal Competition Details

How American utilizes its cash?

To perform a cash flow analysis of American Renal, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash American Renal is receiving and how much cash it distributes out in a given period. The American Renal cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. American Renal Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at 34.94 Million

Payment of 2588 shares by Don Williamson of American Renal subject to Rule 16b-3

Legal trades by American Renal insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

American insider trading alert for payment of common stock by Don Williamson, EVP Chief Operating Officer, on 21st of September 2020. This event was filed by American Renal Associates with SEC on 2020-09-21. Statement of changes in beneficial ownership - SEC Form 4. Don Williamson currently serves as chief operating officer, executive vice president of American Renal Assoc [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

About Contributor